GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PharmChem Inc (OTCPK:PCHM) » Definitions » Piotroski F-Score

PharmChem (PharmChem) Piotroski F-Score : 6 (As of May. 13, 2024)


View and export this data going back to 2003. Start your Free Trial

What is PharmChem Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmChem has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PharmChem's Piotroski F-Score or its related term are showing as below:

PCHM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 13 years, the highest Piotroski F-Score of PharmChem was 6. The lowest was 3. And the median was 5.


PharmChem Piotroski F-Score Historical Data

The historical data trend for PharmChem's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem Piotroski F-Score Chart

PharmChem Annual Data
Trend Dec93 Dec94 Dec95 Dec96 Dec97 Dec98 Dec99 Dec00 Dec01 Dec02
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.00 7.00 5.00 2.00 7.00

PharmChem Quarterly Data
Jun99 Sep99 Dec99 Mar00 Jun00 Sep00 Dec00 Mar01 Jun01 Sep01 Dec01 Mar02 Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Sep22 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 4.00 3.00 6.00

Competitive Comparison of PharmChem's Piotroski F-Score

For the Diagnostics & Research subindustry, PharmChem's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmChem's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PharmChem's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PharmChem's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Mar03) TTM:
Net Income was -0.555 + 0.249 + 0.222 + 0.223 = $0.14 Mil.
Cash Flow from Operations was 0.205 + -0.746 + 0 + 0 = $-0.54 Mil.
Revenue was 7.114 + 6.942 + 1.426 + 1.564 = $17.05 Mil.
Gross Profit was 1.569 + 1.664 + 0.931 + 1.035 = $5.20 Mil.
Average Total Assets from the begining of this year (Mar03)
to the end of this year (Sep23) was
(20.829 + 19.851 + 18.458 + 0 + 3.252) / 5 = $15.5975 Mil.
Total Assets at the begining of this year (Mar03) was $20.83 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $3.25 Mil.
Total Current Liabilities was $0.68 Mil.
Net Income was -0.208 + -0.825 + 0.049 + -0.733 = $-1.72 Mil.

Revenue was 8.066 + 7.316 + 7.227 + 6.335 = $28.94 Mil.
Gross Profit was 1.817 + 1.526 + 1.921 + 1.21 = $6.47 Mil.
Average Total Assets from the begining of last year (Mar02)
to the end of last year (Mar03) was
(28.224 + 25.325 + 23.721 + 22.667 + 20.829) / 5 = $24.1532 Mil.
Total Assets at the begining of last year (Mar02) was $28.22 Mil.
Long-Term Debt & Capital Lease Obligation was $0.61 Mil.
Total Current Assets was $8.39 Mil.
Total Current Liabilities was $10.60 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmChem's current Net Income (TTM) was 0.14. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmChem's current Cash Flow from Operations (TTM) was -0.54. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar03)
=0.139/20.829
=0.00667339

ROA (Last Year)=Net Income/Total Assets (Mar02)
=-1.717/28.224
=-0.06083475

PharmChem's return on assets of this year was 0.00667339. PharmChem's return on assets of last year was -0.06083475. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PharmChem's current Net Income (TTM) was 0.14. PharmChem's current Cash Flow from Operations (TTM) was -0.54. ==> -0.54 <= 0.14 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar03 to Sep23
=0/15.5975
=0

Gearing (Last Year: Mar03)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar02 to Mar03
=0.606/24.1532
=0.02508984

PharmChem's gearing of this year was 0. PharmChem's gearing of last year was 0.02508984. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=3.251/0.683
=4.75988287

Current Ratio (Last Year: Mar03)=Total Current Assets/Total Current Liabilities
=8.391/10.597
=0.79182788

PharmChem's current ratio of this year was 4.75988287. PharmChem's current ratio of last year was 0.79182788. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PharmChem's number of shares in issue this year was 5.021. PharmChem's number of shares in issue last year was 5.853. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5.199/17.046
=0.30499824

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6.474/28.944
=0.2236733

PharmChem's gross margin of this year was 0.30499824. PharmChem's gross margin of last year was 0.2236733. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar03)
=17.046/20.829
=0.81837822

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar02)
=28.944/28.224
=1.0255102

PharmChem's asset turnover of this year was 0.81837822. PharmChem's asset turnover of last year was 1.0255102. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmChem has an F-score of 6 indicating the company's financial situation is typical for a stable company.

PharmChem  (OTCPK:PCHM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PharmChem Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PharmChem's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmChem (PharmChem) Business Description

Traded in Other Exchanges
N/A
Address
2411 E. Loop 820 N, Fort Worth, TX, USA, 76118
PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.
Executives
Alto Investors Palo 10 percent owner 470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp 10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire 08-11-2021